TSX: CPH 18.10 +0.13 +0.72% Volume: 151,576 December 19, 2014
NASDAQ: CPHR 16.07 +0.57 +3.68% Volume: 10,106 December 19, 2014

Cipher Pharmaceuticals is a growing specialty pharmaceutical company that commercializes novel formulations of successful, currently marketed molecules.

Cipher's first product is a fenofibrate formulation marketed in the United States as Lipofen®. Cipher's second product, an extended-release tramadol, is marketed in the United States as ConZip® and in Canada as Durela®. Cipher's third product, a novel formulation of the acne treatment isotretinoin, was launched in the United States in Q4 2012 as Absorica™. The product was also recently launched in Canada as Epuris®.